Who is sponsoring NCT00266669?

NCT00266669 is sponsored by MediQuest Therapeutics.

What drugs are being tested in NCT00266669?

Interventions in NCT00266669: Topical organogel with nitroglycerin.

What condition does NCT00266669 study?

NCT00266669 studies Raynaud's Disease.

Is NCT00266669 still recruiting?

NCT00266669 is currently completed. Last updated 6 August 2007.

Last reviewed 2007-08-06 · How we verify

NCT00266669

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon

Completed Phase 3 Last updated 6 August 2007

What this trial tests

Phase 3 trial testing Topical organogel with nitroglycerin in Raynaud's Disease in 200 participants. Completed in 1 May 2006.

Timeline

1 December 2005

1 May 2006

Quick facts

Lead sponsor	MediQuest Therapeutics
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	1 December 2005
Estimated completion	1 May 2006
Sites	19 locations across United States, Canada

Drugs / interventions tested

Topical organogel with nitroglycerin — full drug profile →

Conditions studied

Raynaud's Disease — all drugs for Raynaud's Disease →

Sponsor

MediQuest Therapeutics — full company profile →

Who can join

Adults 18 to 70, any sex, with Raynaud's Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Improvements in Raynaud's Assessment Score comparing active to placebo
Reduction of number of Raynaud's events
Decrease in duration of Raynaud's events
Decrease in symptoms associated with Raynaud's
Assess safety: frequency and severity of adverse events associated with the study drug

Sponsor's own description

The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin, in comparison to a matching placebo, for patients with moderate to severe primary Raynaud's phenomenon or patients with Raynaud's phenomenon secondary to autoimmune diseases, such as scleroderma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials.
Gladue H, Maranian P, Paulus HE, Khanna D. · · 2013 · cited 28× · PMID 22972592 · DOI 10.1002/acr.21858
Vasodilators for primary Raynaud's phenomenon.
Su KY, Sharma M, Kim HJ, Kaganov E, et al · · 2021 · cited 15× · PMID 33998674 · DOI 10.1002/14651858.cd006687.pub4

Verify or expand the search:

Other recruiting trials for Raynaud's Disease

Currently open trials in the same condition.

NCT07112183 — Open Label Treprostinil Raynaud's Study · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00266669 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MediQuest Therapeutics
Last refreshed: 6 August 2007

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00266669.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing